摘要
淋巴瘤是一类起源于淋巴结和淋巴组织的异质性肿瘤。表观遗传学为研究不改变DNA序列,基因表达改变可遗传的一门新兴学科。淋巴瘤的发病、进展与表观遗传异常密切相关。针对表观遗传异常的靶向药物,主要包括DNA甲基转移酶抑制剂(DNA methyltransferase inhibitors,DNMTis)、组蛋白去乙酰化酶抑制剂、EZH2抑制剂、PRMT抑制剂及BET抑制剂等,在淋巴瘤的靶向治疗中凸显出绝对优势。本文分析近年来表观遗传药物在淋巴瘤中的治疗进展,旨在为淋巴瘤的靶向治疗提供新思路。
Lymphomas are a group of heterogeneous tumors originating from lymphocytes at various stages of differentiation.Epigenetics is an emerging discipline of science that studies heritable changes in the DNA sequences and gene expression patterns of organisms.Studies have shown that the development and progression of lymphomas are closely related to epigenetic abnormalities.Drugs targeting epigenetic abnormalities,including DNA methyltransferase inhibitors,histone deacetylase inhibitors,EZH2 inhibitors,PRMT inhibitors,and BET inhibitors,have been studied extensively and have shown many advantages in the treatment of lymphomas.This article reviews the recent advances in epigenetic drugs for treatment of lymphomas to provide new ideas for treatment strategies for lymphoma.
作者
苗昭艺
赵智刚
Zhaoyi Miao;Zhigang Zhao(Department of Hematology,Tianjin Medical University Cancer Institute and Hospital,National Clinical Research Center for Cancer,Tianjin Key Laboratory of Cancer Prevention and Therapy,Tianjin's Clinical Research Center for Cancer,Tianjin 300060,China)
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2020年第7期359-364,共6页
Chinese Journal of Clinical Oncology
基金
国家自然科学基金项目(编号:81670102,81870150)
天津市自然科学基金项目(编号:16JCYBJC25200)资助。
